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Original Article
Clinical Trial Participation among Ethnic/Racial
Minority and Majority Patients with Advanced Cancer:
What Factors Most Influence Enrollment?
Rachel Jimenez, MD,1 Baohui Zhang, MS,2 Steven Joffe, MD, MPH,3 Matthew Nilsson, BS,2
Lorna Rivera, PhD,4 Jan Mutchler, PhD,5 Christopher Lathan, MD, MS, MPH,6
M. Elizabeth Paulk, MD,7 and Holly G. Prigerson, PhD2,6,8
Abstract
Background: Studies using administrative data report that racial/ethnic minority patients enroll in clinical trials
less frequently than white patients. We studied a cohort of terminally ill cancer patients to determine a) if racial/
ethnic minority patients have lower rates of drug trial enrollment than white patients once socioeconomic
characteristics are accounted for and b) what factors most influence drug trial enrollment among patients with
advanced canceroverall.
Methods: Coping with Cancer (CwC) is a National Cancer Institute/National Institute of Mental Health (NCI/
NIMH)-funded multisiteAU1 c , prospective, longitudinal study of patients with advanced cancer. Baseline interviews
assessed drug trial enrollment as well as socioeconomic characteristics. Logistic regression models estimated
associations between drug trial enrollment and baseline characteristics. Stepwise, backward, and subset model
selection was applied to select the final model where characteristics significant at a = 0.05 remained in the model.
Results: At a median of 4.4 months prior to death, 35 of 358 patients (9.8%) were enrolled in a drug trial. In
unadjusted analyses, race/ethnicity, health insurance, performance status, recruitment site, cancer type, pref-
erence for life-extending care, and lack of end-of-life care planning were associated ( p < 0.05) with enrollment. In
multivariable analysis, patient race/ethnicity was not significantly associated with enrollment. Patients who
reported not having an end-of-life discussion (AU2 c adjusted odds ratio [AOR], 0.18; 95% confidence interval [CI]
0.04–0.83) and those not wanting to discuss life expectancy (AOR, 0.31; 95%CI 0.12–0.79) were more likely to be
trial enrollees.
Conclusion: Patient race/ethnicity was not associated with clinical trial enrollment after adjustment for socio-
economic covariates. Patients with advanced cancer endorsing less engagement in end-of-life planning were
more likely to be enrolled in a clinical trial.
Introduction
Enrollment of American cancer patients in clinicaltrials has remained modest despite significant progress in
cancer care as well as the federal government’s own com-
mitment to increasing participation over the past two
decades.1 Less than 5% of all adult cancer patients participate
in a clinical trial.2–4 Low rates of enrollment delay discovery of
potentially life-sustaining therapies.
Of particular concern is the oft-cited underenrollment of
racial and ethnic minorities. Rates of minority enrollment are
conflicting. Some studies conclude that racial minorities enroll
in clinical trials at a significantly lower rate than their non-
minority counterparts2,3; others suggest that racial minorities
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enroll in clinical trials at rates that parallel their respective
incidence of disease.4
These prior studies used large databases that provide little
additional information about the patient’s social or economic
identity. The lack of such information is problematic given
that psychosocial and economic factors may influence patient
decision making, particularly when a patient has a limited
life-expectancy.
Recent research on cancer care disparities supports this
idea. Bhargava and Du5 demonstrated that although black
patients were less likely than their white counterparts to re-
ceive adjuvant chemotherapy for lymph-node-positive breast
cancer at baseline, adjusted analyses that accounted for eco-
nomic status attenuated the difference in care received.
Similarly, Schwartz and colleagues6 found that both access to
care and socioeconomic status ameliorated initial disparities
observed in the cancer care and cancer-specific survival be-
tween black and white prostate cancer patients. Analyses of
hospice utilization between white and black patients have
also demonstrated similar results.7
The primary objective of this study was to examine the
association between the race/ethnicity of patients with ad-
vanced cancer and their participation in drug trials. We hy-
pothesized that enrollment in a drug trial would not be
associated with racial/ethnic affiliation when socioeconomic
and psychosocial factors were taken into account. Our second
aim was to determine the factors most associated with drug
trial enrollment overall in this cohort of patients with ad-
vanced cancer.
Patients and Methods
Coping with Cancer (CwC) is a multisite study of patients
with advanced cancer designed to examine the psychosocial
attitudes, mental health, and health care preferences of a co-
hort of terminally ill cancer patients. Patients were recruited
from seven outpatient cancer facilities between September of
2002 and August of 2008: Dana-Farber/Partners Cancer
Center (Boston, MA), New Hampshire Oncology-Hematology
(Londonderry, NH), Memorial Sloan-Kettering Cancer
Center (New York, NY), Parkland Hospital (Parkland, TX),
Simmons Comprehensive Cancer Center (University of
Texas-Southwestern in Dallas, TX), West Haven Veterans
Affairs Comprehensive Cancer Center, (West Haven, CT),
and Yale Cancer Center (New Haven, CT). The institutional
review board of each facility approved the study protocol.
A trained rater interviewed patients and caregivers indi-
vidually in face-to-face encounters. Each rater received
training in interview practices prior to initiation of the study
and met preestablished criteria (e.g., kappa ratings of 0.90 or
higher on psychiatric diagnoses between new and trained
interviewers) before being permitted to conduct interviews
for the study. All interviews were conducted in English or
Spanish.
To meet criteria for inclusion, patients had to meet the
following requirements. First, eligible patients must have had
a diagnosis of either an advanced pulmonary, gastrointesti-
nal, or brain cancer. These cancer types were selected to en-
sure inclusion of patients who, by virtue of tumor biology,
would have a limited life expectancy. For the purposes of this
study, advanced cancer was defined as either the presence of
distant metastases or locoregional disease refractory to first-
line chemotherapy. Other requirements for enrollment in-
cluded: age greater than 20 years to ensure recruitment of an
adult cancer population using the National Institutes of
Health (NIH) definition of children as an individual age 20
years or below, the use of English or Spanish as the patient’s
primary language, and the absence of significant cognitive
impairment (e.g., dementia, delirium) as determined by
physician assessment at the time of the baseline screening
interview. Medical staff and the interviewer determined
whether at the time of enrollment the patient had adequate
stamina to complete the interview. All participants signed
written informed consent.
Of 1015 eligible patients, 726 (71.5%) enrolled. For the
purposes of this study, only patients who were deceased at
the time of study closure and had nonmissing data for
clinical trial enrollment at baseline were included to ensure
selection of patients with terminal disease. This final cohort
of 358 patients did not differ significantly ( p < 0.05) by can-
cer type, psychological distress, or rates of psychiatric dis-
orders from the study participants at large. However, this
cohort had a worse performance status, a higher symptom
burden, and a lower baseline quality of life as would be
expected in a cohort with shorter life expectancy. They were
also more likely to be younger, female, uninsured, less ed-
ucated, and to identify as a member of a racial or ethnic
minority group.
Within the 358 patients included in this study, a subgroup
sample with nonmissing data for the statistically significant
confounders included in the multiple logistic regression
analysis (n = 325) had significantly ( p < 0.05) lower income
and educational levels, was less likely to be married, less
likely to have health insurance, less likely to be white or
Jewish, and had worse performance status and higher
symptom burden compared with the 33 patients not included
in the final multiple regression analysis.
Primary outcome
Drug trial enrollment. Enrollment in a clinical trial was
determined through chart review performed by a member of
the patient’s care team to answer the question, ‘‘Is the patient
on a drug trial? If yes, what phase drug trial?’’
Associations of interest
Patient race/ethnicity. As part of the patient interview,
participants were asked: ‘‘What race or ethnicity do you
consider yourself to be?’’ Responses were: ‘‘white,’’ ‘‘black,’’
‘‘Asian-American, Pacific Islander or Indian,’’ ‘‘Hispanic,’’
‘‘other,’’ ‘‘refused,’’ or ‘‘don’t know.’’
Other covariates of interest
Patient factors that could also influence a patient’s enroll-
ment in a clinical trial were examined as potential con-
founders. These included:
Sociodemographic traits. These included patient’s self-
reported sex, age, religion, marital status, education, income,
and health insurance coverage.
Recruitment site. The site was the location where the
patient received treatment, for example, the Dana Farber
Cancer Institute, Parkland Hospital.
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Yes (n = 35;
9.78%)







White 235 (66.01%) 29 (12.3%) 206 (87.7%) 2.70 (1.09–6.69) 0.032
Black 61 (17.13%) 2 (3.3%) 59 (96.7%) 0.27 (0.06–1.15) 0.077
Hispanic 53 (14.89%) 2 (3.8%) 51 (96.2%) 0.32 (0.08–1.38) 0.127
Asian 4 (1.12%) 2 (50.0%) 2 (50.0%) 9.67 (1.32–70.89) 0.026
Sociodemographics
Age; mean (SD) 58.58 (12.66) 56.09 (11.59) 58.86 (12.76) 0.98 (0.96–1.01) 0.219
Male 194 (54.19%) 15 (7.73%) 179 (92.27%) 0.59 (0.29–1.20) 0.149
Family Income ‡ $31,000 113 (31.56%) 11 (9.73%) 102 (90.27%) 1.62 (0.58–4.55) 0.362
Married 217 (60.61%) 24 (11.06%) 193 (88.94%) 1.41 (0.67–2.99) 0.365
Insured 220 (61.45%) 32 (14.55%) 188 (85.45%) 7.26 (2.18–24.22) 0.001
Education; mean (SD) 12.55 (4.09) 13.54 (3.58) 12.44 (4.14) 1.08 (0.98–1.18) 0.130
Religion
Catholic 132 (36.87%) 16 (12.12%) 116 (87.88%) 1.49 (0.74–3.01) 0.267
Protestant 61 (17.04%) 3 (4.92%) 58 (95.08%) 0.43 (0.13–1.44) 0.168
Jewish 17 (4.75%) 5 (29.41%) 12 (70.59%) 4.29 (1.42–13.01) 0.010
Muslim 4 (1.12%) 1 (25.00%) 3 (75.00%) 3.12 (0.32–30.82) 0.330
No religion 16 (4.47%) 1 (6.25%) 15 (93.75%) 0.60 (0.08–4.68) 0.626
Pentecostal 9 (2.51%) 1 (11.11%) 8 (88.89%) 1.15 (0.14–9.48) 0.896
Baptist 53 (14.80%) 2 (3.77%) 51 (96.23%) 0.32 (0.07–1.38) 0.127
Recruitment site
Yale Cancer Center 68 (18.99%) 21 (30.88%) 47 (69.12%) 8.78 (4.17–18.46) 0.000
Veterans Affairs CCC 12 (3.35%) 0 (0.00%) 12 (100.0%) --------a 0.983
Simmons Center 34 (9.50%) 3 (8.82%) 31 (91.18%) 0.88 (0.25–3.04) 0.840
Parkland Hospital 141 (39.39%) 4 (2.84%) 137 (97.16%) 0.17 (0.06–0.51) 0.001
DFCI/MGH 8 (2.23%) 1 (12.50%) 7 (87.50%) 1.32 (0.16–11.08) 0.796
New Hampshire Heme/Onc 65 (18.2%) 2 (3.1) 63 (96.9) 0.25 (0.06–1.07) 0.061
Cancer type
Lung 76 (21.23%) 3 (3.95%) 73 (96.05%) 0.32 (0.10–1.08) 0.066
Pancreatic 33 (9.22%) 9 (27.27%) 24 (72.73%) 4.31 (1.82–10.24) 0.001
Gallbladder 7 (1.96%) 0 (0.00%) 7 (100.0%) --------a 0.987
Colon 45 (12.57%) 5 (11.11%) 40 (88.89%) 1.18 (0.43–3.21) 0.747
Brain 8 (2.23%) 2 (25.00%) 6 (75.00%) 3.20 (0.62–16.51) 0.164
Stomach 14 (3.91%) 1 (7.14%) 13 (92.86%) 0.70 (0.09–5.53) 0.737
Esophageal 12 (3.35%) 3 (25.00%) 9 (75.00%) 3.27 (0.84–12.70) 0.087
Performance status; mean (SD)
Karnofsky Score 64.32 (16.54) 71.18 (18.05) 63.58 (16.23) 1.03 (1.01–1.06) 0.012
Zubrod Score 1.72 (0.91) 1.37 (0.94) 1.75 (0.9) 0.60 (0.39–0.92) 0.020
Charlson Index 8.34 (2.68) 7.03 (2.23) 8.48 (2.69) 0.80 (0.70–0.93) 0.003
McGill Quality of Life; mean (SD)
Physical functioning 5.61 (2.66) 5.89 (1.99) 5.58 (2.72) 1.04 (0.91–1.20) 0.524
Symptoms 5.36 (2.13) 6.2 (1.6) 5.27 (2.17) 1.22 (1.04–1.44) 0.016
Psychological 7.22 (2.5) 7.46 (2.2) 7.2 (2.53) 1.04 (0.90–1.21) 0.563
Support 8.63 (1.67) 8.31 (1.44) 8.67 (1.69) 0.89 (0.74–1.08) 0.239
Summative score 6.79 (1.55) 6.98 (1.12) 6.76 (1.59) 1.10 (0.87–1.38) 0.431
Doctor-patient relationship
How much trust your doctor; mean (SD)
(n = 121)
3.34 (1.20) 3.29 (1.50) 3.34 (1.19) 0.96 (0.52–1.78) 0.90
How much respect your doctor; mean
(SD) (n = 121)
3.45 (1.18) 3.29 (1.50) 3.46 (1.16) 0.89 (0.50–1.58) 0.70
Comfortable asking questions about
your care (n = 329)
0.89 (0.24) 0.87 (0.28) 0.89 (0.24) 0.74 (0.19–2.94) 0.67
EOL treatment preferences
Extend life preference 83 (23.18%) 13 (15.66%) 70 (84.34%) 2.56 (1.15–5.71) 0.022
Against ICU death 121 (33.80%) 12 (9.92%) 109 (90.08%) 1.08 (0.51–2.32) 0.836
Prefer feeding tube 125 (34.92%) 10 (8.00%) 115 (92.00%) 0.76 (0.34–1.67) 0.491
Prefer ventilator 84 (23.46%) 8 (9.52%) 76 (90.48%) 1.04 (0.44–2.43) 0.930
Prefer chemotherapy 248 (69.27%) 27 (10.89%) 221 (89.11%) 4.28 (0.99–18.44) 0.051
Prefer antibiotics 199 (55.59%) 21 (10.55%) 178 (89.45%) 1.64 (0.70–3.82) 0.255
(continued)
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Cancer type. The cancer type was the tissue of origin, for
example, lung, pancreas, gallbladder, colon, stomach, or
esophagus.
Patient health. The patient’s Karnofsky, Zubrod, and
Charlson comorbidity index scores were documented by a
member of the medical team. A high Karnofsky score implies
a better performance status, whereas a low score on the
Zubrod or Charlson comorbidity index reflects a higher per-
formance status. The McGill Quality of Life Index was also
administered by trained raters at the time of interview, where
a high score implies a higher quality of life.8–11
Doctor-patient relationship. Patients were asked several
questions about the relationship they had with their physician
using The Human Connection Scale. Sample questions included:
‘‘How much do you trust your doctor?,’’ ‘‘How much do you
respect your doctor?,’’ and ‘‘To what extent do you feel com-
fortable asking your doctor questions?’’ Answers were graded
on a scale of 1 to 4, where a score of 1 corresponded to ‘‘Not at
all’’ and a score of 4 corresponded to ‘‘A large extent.’’12
End-of-life treatment preferences. Patients were asked
about the kind of medical care they would like to receive at the
end of their life. For example: ‘‘If you could choose, would you
prefer: 1) treatment that focused on extending life as much as
possible, even if it meant more pain and discomfort, or 2) care that
focused on relieving pain and discomfort as much as possible,
even if that meant not living as long?’’ They were also asked
specific yes/no questions including: ‘‘Would you want to be kept
alive if it required being on a feeding tube?’’ or ‘‘Would you want
to be kept alive if it required you being on a breathing machine?’’
Advance care planning. Patients were asked a series of
yes/no questions to ascertain their preferences for end-of-life
care. These questions included: ‘‘Have you and your doctor
discussed any particular wishes you have about the care you
would want to receive if you were dying?,’’ ‘‘If your doctor
knew how long you had left to live, would you want him or
her to tell you?,’’ ‘‘Do you have a signed living will, or health
care proxy, or durable power of attorney for health care?,’’
and ‘‘Have you completed a do not resuscitate (DNR) order?’’
Statistical analysis
Ttest, Cochran-Mantel-Haenszel test, and v2 test statistics
were used, as appropriate, to test for significant differences
between patients who did or did not report clinical trial en-
rollment at baseline. Multivariable logistic regression model-
ing was used to examine the association between clinical trial
enrollment and the baseline patient characteristics that were
significant in bivariate analyses. Stepwise, backward, and
subset model selection procedures were applied to select the
remaining significant confounders with an entry significance
level of a = 0.2 and a stay significance level of a = 0.1. Only
baseline characteristics significant at a = 0.05 remained in the
model. Factors that were significantly related both to race/
ethnicity and to trial enrollment, and that rendered the effect
of race/ethnicity on trial enrollment not statistically signifi-
cant (i.e., p > 0.05) were considered confounders.
Statistical analyses were performed with SAS version 9.2
(SAS Institute, Cary, NC). We report two-tailed p values.
Results
Baseline patient characteristics: Univariate
analysis
The cohort of patients with advanced cancer died a median
of 4.4 months after the baseline assessment. Baseline charac-
teristics are detailed in b T1Table 1. In this study, 9.8% of patients
(n = 35) were enrolled in a drug trial at some point during their
cancer care, of which 8 patients (22.9%) were enrolled in a
Phase I study, 9 patients (25.7%) were enrolled in a Phase II
study, 7 patients (20%) were enrolled in a Phase III study, and
the remaining 11 (31.4%) were not specified.
In univariate analysis, white or Asian race, Jewish religion,
medical insurance, receiving care at Yale Cancer Center, pri-
mary pancreatic cancer, a better performance status, and
fewer physical symptoms of illness were all significantly
( p < 0.05) associated with clinical trial enrollment (Table 1).
Patients who preferred life-extending care, those who did not
want their doctor to tell them their life expectancy, and those
who reported not having had an end-of-life discussion with
their physician, were also more likely to be enrolled in a
clinical trial at baseline (all p < 0.05).
Factors associated with clinical trial enrollment:
Multivariable analysis
After adjustment for demographic and socioeconomic
covariates including age, gender, marital status, insurance,
and education, white race was not associated with clinical
trial enrollment. Patients who reported that they did not have






Yes (n = 35;
9.78%)







Terminal Illness acknowledgement 125 (34.92%) 9 (7.20%) 116 (92.80%) 0.62 (0.27–1.39) 0.243
End-of-life discussion 151 (42.18%) 6 (3.97%) 145 (96.03%) 0.25 (0.10–0.62) 0.003
Want doctor to tell life-expectancy 236 (65.92%) 16 (6.78%) 220 (93.22%) 0.39 (0.18–0.85) 0.017
Completed DNR order 138 (38.55%) 8 (5.80%) 130 (94.20%) 0.46 (0.20–1.06) 0.067
Had living will or DPA 181 (50.56%) 18 (9.94%) 163 (90.06%) 1.08 (0.51–2.28) 0.843
aEstimate could not be obtained.
DNR, do not resuscitate; DPA, __________; EOL, end of life; ICU, intensive care unit; SD, standard deviation. b AU3
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ratio, [AOR] 0.18; 95% confidence interval [CI] 0.04–0.83;
p = 0.03), those who did not want their doctor to tell them their
life expectancy (AOR, 0.31; 95%CI 0.12–0.79; p = 0.01), and
those treated at Yale Cancer Center were more likely to be
enrolled in a clinical trial. Patients with a primary lung cancer
were less likely to be enrolled in a clinical trial (T2 c Table 2). The
remaining factors identified in the unadjusted analysis did not
meet criteria ( p < 0.05) for significance.
Confounders of the race/ethnicity effect
on trial enrollment
Patient race/ethnicity was found to be statistically signifi-
cant in predicting trial enrollment in the univariate analysis.
Analyses were performed to test whether the other factors
associated with clinical trial enrollment confounded the rela-
tionship between race and trial enrollment. The analyses
compared patients who self-identified as ‘‘white’’ versus all
other participants (‘‘nonwhite’’) because the individual ra-
cial/ethnic groups did not have an adequate number of trial
participants to yield reliable estimates. A confounding effect
of white race on the likelihood of trial enrollment was ob-
served for patient recruitment site (Yale Cancer Center,
Parkland Hospital) and health insurance coverage (T3 c Table 3).
Other factors including education, Jewish and Baptist reli-
gion, and pancreatic cancer were found to be partial con-
founders of trial enrollment.
Discussion
Consistent with prior studies of minority clinical trial en-
rollment, we found white patients were more likely to be
enrolled in a clinical drug trial compared to nonwhite pa-
tients. Yet, in support of our hypothesis, when demographic
and socioeconomic factors were accounted for, race did not
remain a significant predictor of enrollment. Specifically,
health insurance coverage and recruitment site proved con-
founders that explained the effect of race on clinical trial
enrollment.
Although we are not the first to report the relationship
between insurance status or location of care and clinical trial
enrollment,3,13–15 our analysis does support the association of
each with minority race/ethnicity and serves to emphasize
that the discrepancy in drug trial enrollment among racial/
ethnic minorities may be one of access to care and not of
cultural acceptance.16 However, although the characteristics
delineated above appear to mitigate the differences in clinical
trial enrollment by patient race, it should not imply that bias,
either explicit or implicit, does not exist or that there is no
longer a need for clinical staff be vigilant about the need to
enroll racial and ethnic minority cancer patients in clinic trials.
With respect to other factors that predicted clinical trial
enrollment, patients with a primary lung cancer were signif-
icantly less likely to enroll in a clinical trial, whereas patients
Table 2. Adjusted Associations of Clinical Trial Enrollment with Baseline Predictors
Clinical trial experience Adjusted result
Total Yes No
Baseline correlate (n = 325) (n = 30, 9.2%) (n = 295, 90.8%) OR/HR P value
End-of-Life discussion 67 (20.6) 2 (6.7) 118 (98.3) 0.18 (0.04–0.83) 0.03
Want doctor to tell life expectancy 70 (21.5) 16 (6.8) 219 (93.2) 0.31 (0.12–0.79) 0.01
Yale Cancer Center 120 (36.9) 21 (31.3) 46 (68.7) 12.26 (1.09–4.84) < 0.0001
Lung cancer 235 (72.3) 3 (4.3) 67 (95.7) 0.17 (0.04–0.72) 0.02
Note: 325 patients had nonmissing data with the four baseline correlates.
HR, ________; OR, odds ratio.
Table 3. Associations between White Race and
Clinical Trial Enrollment Controlling for




(95% CI)a P value
White race (base model) 356 2.70 (1.09–6.69)b 0.03
Plus age 356 3.15 (1.24–8.00) 0.02
Plus male 356 2.75 (1.11–6.83) 0.03
Plus health insured 350 1.33 (0.50–3.58) 0.57
Plus education 356 2.38 (0.89–6.41) 0.09
Plus Protestant religion 356 2.94 (1.18–7.33) 0.02
Plus Jewish religion 356 2.37 (0.94–5.97) 0.07
Plus Baptist religion 356 2.42 (0.97–6.06) 0.06
Plus Yale Cancer
Center
356 1.96 (0.76–5.07) 0.17 b AU3
Plus Parkland Hospital 356 1.13 (0.40–3.22) 0.82
Plus New Hampshire
Heme/Onc
356 3.59 (1.44–9.00) 0.006
Plus Pancreatic cancer 356 2.30 (0.91–5.79) 0.08
Plus Brain cancer 356 2.62 (1.05–6.52) 0.04
Plus Lung cancer 356 2.78 (1.12–6.93) 0.03
Plus Esophageal cancer 356 2.72 (1.09–6.76) 0.03
Plus Karnofsky score 348 2.56 (1.02–6.41) 0.04
Plus Zubrod score 350 2.61 (1.05–6.50) 0.04
Plus Charlson Index 355 2.96 (1.19–7.41) 0.02
Plus End-of-life
discussion
355 3.18 (1.27–7.97) 0.01
Plus want doctor to tell
life-expectancy
325 3.33 (1.22–9.05) 0.02
Plus general self-
efficacy
317 2.94 (1.09–7.95) 0.03
Plus extend life
preference
289 3.02 (1.08–8.40) 0.03
Plus prefer
chemotherapy
319 3.26 (1.20–8.83) 0.02
Plus completed DNR
order
322 3.73 (1.37–10.19) 0.01
Plus McGill symptoms 354 2.99 (1.19–7.50) 0.02
aThe adjusted ORs account for demographic and psychosocial
variables.
bThe OR for the base model is unadjusted.
Sample sizes vary due to missing data.
AOR, adjusted odds ratio; CI, confidence interval; DNR, do not
resuscitate.
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treated at the Yale Cancer Center, those not reporting having
had an end-of-life discussion with one’s physician, and those
not wanting a physician to relay one’s life expectancy were all
positively associated with clinical trial participation. It is un-
clear why patients with lung cancer were less likely to enroll
in a trial compared with the cohort at-large, although other
logistical factors historically thought to impact trial enroll-
ment and not captured by our study, including physician
preference, trial availability, or distance from a participating
trial center could have played a role.3 In reference to the as-
sociation between Yale Cancer Center and trial enrollment, as
mentioned in a prior report,17 this site appeared to treat all our
enrolled patients more aggressively compared with other
participating sites, with both higher rates of aggressive care
and lower utilization of hospice care than other participating
medical centers.
Of particular interest was the finding that all patients who
had enrolled in a drug trial were significantly less likely to
report having had an end-of-life discussion with their doctor
and were also significantly less likely to want to know their
life expectancy from their physician even after controlling for
numerous potential confounders (Table 1). As all responses in
our study relied on patient recall, we cannot know if end-of-
life care conversations were never held between patients and
their doctors or if patients simply did not remember such
discussions. Yet, this is the first study that we know of to find
a significant association between clinical trial enrollment and
patient lack of interest in life expectancy and reporting of end-
of-life discussions. This association does suggest an interac-
tion between terminal illness engagement and the receipt of
experimental medical care.
Previously published research about end-of-life care has
shown that patients who do not report an end-of-life discus-
sion with their physician are more likely to receive aggressive,
costly medical care, and both aggressive care and higher
health care costs are associated with a worse quality of
death.17–19 Racial minorities in particular are more likely to
present with advanced disease and more likely to receive
aggressive end-of-life care.18,20 In light of the results of this
report, it appears that both minority and majority ethnic sta-
tus terminally ill patients who participate in clinical trials are
likely to benefit from counseling regarding end-of-life care
planning.
There are several limitations to this study. First, our study is
limited by the modest number of patients who participated in a
clinical trial. Consequently, we may have failed to detect some
factors that are associated with trial enrollment that might
emerge in larger samples. Second, our trial was restricted to
patients who spoke either English or Spanish as their primary
language. Patients belonging to racial or ethnic groups where a
language other than English or Spanish is primarily spoken
would have been excluded from our study and therefore, we
can draw limited conclusions regarding clinical trial enrollment
rates in these populations. Furthermore, the design of this trial
did not permit the coding of ethnicity as a separate variable
from race. Hence, this could have resulted in the grouping of a
subset of patients with Hispanic ethnicity into a different cate-
gory, for example, white or black. However, as patients were
asked to self-identify using a list of choices, they were free to
select the option with which they most identified. Therefore, we
believe that the potential impact of this choice is unlikely to be
profound.
Finally, whereas our study attempted to delineate some of
the psychosocial factors that could influence trial enrollment
in a cohort of patients with advanced cancer, a multitude of
factors remain that could not be addressed within this anal-
ysis. For example, this study lacked information regarding
patients’ eligibility for, or knowledge of, available clinical
trials. Therefore, we can draw no conclusions about the rea-
sons why the participants in our study were or were not en-
rolled in a trial. We also have no information regarding a
patient’s enrollment in a nondrug trial as all patients were
only screened for participation in a drug trial. Additionally,
the timing of patient’s trial enrollment and their diagnosis of
advanced cancer is unknown, so some patients may have
enrolled in a clinical trial before they were considered to have
advanced disease, or after our baseline assessment, and these
data were not captured in the present analysis.
Despite these limitations, our study demonstrates that pa-
tients with advanced cancer self-identifying as Asian, black,
or Hispanic are equally likely to enroll in a clinical trial as their
white counterparts when socioeconomic and clinical factors
are taken into account. Additionally, patients with advanced
cancer who do enroll in drug trials are less likely to report an
end-of-life care discussion or to want to know their life ex-
pectancy than patients with no history of drug trial partici-
pation. Additional research is required to explore further
nuances of the doctor-patient interaction as it relates to end-
of-life care discussions and clinical trial decision making. In
the interim, this study suggests a tension between advance
care planning and drug trial participation. It also underscores
the importance of end-of-life care planning for patients par-
ticipating in clinical trials.
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